Sydney, Australia 25 August 2021 Clarity Pharmaceuticals lists on the ASX today under code CU6 after raising $92.0 million at $1.40 per share, equating to an indicative market capitalisation of approximately $358.6million (on an undiluted basis) at the Offer price. Clarity is an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing…
Sydney, Australia 25 August 2021 – Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has been dosed with 64Cu SAR-bisPSMA in the dosimetry phase of the SECuRE clinical trial (NCT04868604)1…
Sydney, Australia, 25 August 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Australian daily newspaper covering the latest business and economic affairs of Australia and the world. The article discusses Clarity’s ASX debut, its key investors and the company’s pipeline of products in development. Read the full article here: https://www.afr.com/companies/healthcare-and-fitness/clarity-pharma-charges-ahead-on-asx-debut-20210824-p58lev
Sydney, Australia, 21 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Australian daily newspaper covering the latest business and economic affairs of Australia and the world. The article discusses Clarity, our history, clinical trials, technology and the initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/companies/healthcare-and-fitness/clarity-pharmaceuticals-to-hit-asx-in-august-20210720-p58b98
Sydney, Australia, 12 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses the terms of Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/street-talk/terms-out-for-clarity-s-358m-ipo-20210712-p588tj
Sydney, Australia, 8 July 2021 – Clarity Pharmaceuticals was featured in the Australian, Australia’s national broadsheet newspaper published by News Corp Australia since 14 July 1964. The article discusses Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.theaustralian.com.au/business/dataroom/clarity-pharmaceuticals-embarks-on-cornerstone-process-for-ipo/news-story/b2824850cb8686e039e68aecb9fafca2
Sydney, Australia, 8 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses Clarity’s initial public offering on the Australian Securities Exchange and option agreement with China Grand Pharmaceuticals and Healthcare.…
Sydney, Australia 8 June 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/street-talk/jefferies-bells-prepare-cancer-play-clarity-for-250m-float-20210608-p57z40
Sydney, Australia 10 August 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been dosed in the 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer. Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very excited to…
Sydney, Australia 28 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient recruitment has commenced with the opening of the…